Skip to main content

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Recruiting · Phase 3 · NCT07011745

Conditions: Alzheimer's Disease

At a glance

Research payments reported, 2025
$42,609
U.S. investigators named
11
Sites paid
9
Planned or actual enrollment
426

About the trial

Sponsor
Bristol-Myers Squibb
Tested
Xanomeline/Trospium Chloride Capsule (drug), Xanomeline Enteric Capsule (drug), Placebo (drug)
Dates
Started 2025-07-16; completion 2028-11-13
Results posted
Not yet

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $42,609 in research payments for this study in 2025 (9 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Envision Trials, Llc $23,311
  • Mountain Neurological Research Center $6,573
  • Epic Medical Research, Llc - Carrolton $4,075
  • Epic Medical Research $3,562
  • Key Clinical Research $1,161
  • Medical College of Wisconsin $1,120
  • Chandler Clinical Trials $1,041
  • Infinity Clinical Trials $1,040
  • Pantheon Clinical Research $726

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.